Price (delayed)
$2.42
Market cap
$83.94M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.24
Enterprise value
$81.14M
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company ...
Highlights
The debt has contracted by 40% YoY
Achieve Life Sciences's EPS has increased by 17% YoY but it has decreased by 12% QoQ
ACHV's net income is down by 34% YoY and by 21% QoQ
Achieve Life Sciences's equity has decreased by 33% QoQ
Key stats
What are the main financial stats of ACHV
MarketValuationsEarnings
Shares outstanding
34.69M
Market cap
$83.94M
Enterprise value
$81.14M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.98
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$39.07M
Net income
-$39.83M
EBIT
-$37.65M
EBITDA
-$37.42M
Free cash flow
-$29.77M
Per shareBalance sheetLiquidity
EPS
-$1.24
EPS diluted
-$1.24
Free cash flow per share
-$0.93
Book value per share
$0.61
Revenue per share
$0
TBVPS
$1.14
Total assets
$38.63M
Total liabilities
$17.73M
Debt
$9.96M
Equity
$20.9M
Working capital
$29.79M
Debt to equity
0.48
Current ratio
5.46
Quick ratio
5.14
Net debt/EBITDA
0.07
MarginsEfficiencyDividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-72%
Return on equity
-110.6%
Return on invested capital
-129.2%
Return on capital employed
-117.8%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ACHV stock price
How has the Achieve Life Sciences stock price performed over time
Intraday
-5.1%
1 week
-16.55%
1 month
-15.09%
1 year
-47.28%
YTD
-31.25%
QTD
-9.36%
Financial performance
How have Achieve Life Sciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$39.07M
Net income
-$39.83M
Gross margin
N/A
Net margin
N/A
ACHV financials
Achieve Life Sciences's operating income has decreased by 43% YoY and by 25% QoQ
ACHV's net income is down by 34% YoY and by 21% QoQ
Growth
What is Achieve Life Sciences's growth rate over time
ACHV growth chart
Valuation
What is Achieve Life Sciences stock price valuation
P/E
N/A
P/B
3.98
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Price to earnings (P/E)
Achieve Life Sciences's EPS has increased by 17% YoY but it has decreased by 12% QoQ
Price to book (P/B)
The P/B is 80% less than the 5-year quarterly average of 21.0 and 7% less than the last 4 quarters average of 4.5
Achieve Life Sciences's equity has decreased by 33% QoQ
Price to sales (P/S)
Efficiency
How efficient is Achieve Life Sciences business performance
Achieve Life Sciences's return on equity has surged by 88% YoY but it has decreased by 2.1% QoQ
Achieve Life Sciences's return on invested capital has surged by 71% YoY and by 7% QoQ
ACHV's ROA is up by 44% year-on-year but it is down by 10% since the previous quarter
Dividends
What is ACHV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ACHV.
Financial health
How did Achieve Life Sciences financials performed over time
Assets vs liabilities
The total assets is 118% more than the total liabilities
The total assets has soared by 99% YoY but it has contracted by 19% from the previous quarter
The quick ratio fell by 20% QoQ
Debt vs equity
The debt is 52% less than the equity
Achieve Life Sciences's debt to equity has soared by 104% YoY and by 55% from the previous quarter
The debt has contracted by 40% YoY
Balance sheet
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from 
and Sharadar.